Published in Int J Radiat Oncol Biol Phys on February 01, 1997
Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer (2010) 1.09
Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy. J Contemp Brachytherapy (2014) 0.91
Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer. Ann Surg Oncol (2015) 0.79
SOR: project methodology. Br J Cancer (2001) 5.24
DNA transformation leads to pilin antigenic variation in Neisseria gonorrhoeae. Nature (1988) 2.98
Anti-proliferative properties of DL-alpha-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun (1978) 2.74
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
DL-alpha-(Difluoromethyl)arginine: a potent enzyme-activated irreversible inhibitor of bacterial decarboxylases. Biochemistry (1981) 2.30
Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene (2006) 2.09
In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol (1998) 1.95
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 1.94
Pilin expression in Neisseria gonorrhoeae is under both positive and negative transcriptional control. EMBO J (1988) 1.88
DNA sequence encoding the NH2-terminal peptide involved in transport of lambda receptor, an Escherichia coli secretory protein. Proc Natl Acad Sci U S A (1980) 1.87
Trypanosoma brucei TBRGG1, a mitochondrial oligo(U)-binding protein that co-localizes with an in vitro RNA editing activity. J Biol Chem (1998) 1.87
Alpha-methyl ornithine, a potent competitive inhibitor of ornithine decarboxylase, blocks proliferation of rat hepatoma cells in culture. Proc Natl Acad Sci U S A (1976) 1.76
malB region in Escherichia coli K-12: specialized transducing bacteriophages and first restriction map. J Bacteriol (1978) 1.74
Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys (1998) 1.70
Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer (1997) 1.67
[An exceptional variety of medulloblastoma: melanotic medulloblastoma]. Ann Pathol (1997) 1.65
Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys (1997) 1.60
Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients. Eur J Cancer (1997) 1.53
Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J Biol Chem (1992) 1.52
Urinary morbidity after 125I brachytherapy of the prostate. BJU Int (2003) 1.50
Synthesis and maturation of lambda receptor in Escherichia coli K-12: in vivo and in vitro expression of gene lamB under lac promoter control. Proc Natl Acad Sci U S A (1980) 1.49
Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer (1995) 1.48
Influence of tumoral, radiobiological, and general factors on local control and survival of a series of 361 tumors of the velotonsillar area treated by exclusive irradiation (external beam irradiation+brachytherapy or brachytherapy alone) Int J Radiat Oncol Biol Phys (1994) 1.44
[High fetal irradiation: about one pregnant woman receiving infradiaphragmatic radiotherapy for Hodgkin lymphoma]. Cancer Radiother (2007) 1.39
["Standards, Options and Recommendations 2001" for radiotherapy in patients with non-metastatic infiltrating breast cancer. Update. National Federation of Cancer Campaign Centers (FNCLCC)]. Cancer Radiother (2002) 1.39
A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene (2011) 1.38
MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis (2013) 1.37
N-2,3-Butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. J Med Chem (1985) 1.36
Genetic study of a membrane protein: DNA sequence alterations due to 17 lamB point mutations affecting adsorption of phage lambda. EMBO J (1983) 1.34
MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol (2000) 1.33
A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol (1993) 1.30
Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys (1999) 1.30
Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys (1997) 1.30
Improved quantification of angiogenesis in the rat aortic ring assay. Angiogenesis (2001) 1.29
Spheroids in radiobiology and photodynamic therapy. Crit Rev Oncol Hematol (2001) 1.29
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J (2001) 1.29
Control of pilus expression in Neisseria gonorrhoeae as an original system in the family of two-component regulators. Mol Microbiol (1991) 1.24
Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res (2001) 1.18
Inhibition of the proteolysis of rat erythrocyte membrane proteins by a synthetic inhibitor of calpain. Biochem Biophys Res Commun (1988) 1.18
High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer (2000) 1.16
Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol (2001) 1.15
Salvage irradiation by brachytherapy of velotonsillar squamous cell carcinoma in a previously irradiated field: results in 73 cases. Int J Radiat Oncol Biol Phys (1994) 1.15
Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. Cancer (2005) 1.12
Occurrence of polyglucosan bodies in temporal lobe epilepsy. J Neurol Neurosurg Psychiatry (1992) 1.12
Specific inhibition of polyamine oxidase in vivo is a method for the elucidation of its physiological role. Biochim Biophys Acta (1985) 1.11
Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci (2003) 1.10
Neisseria gonorrhoeae prepilin export studied in Escherichia coli. J Bacteriol (1991) 1.09
alpha-difluoromethyl DOPA, a new enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase. J Neurochem (1978) 1.09
Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer (1998) 1.07
Antimalarial polyamine analogues. J Med Chem (1991) 1.06
Stroke risk in patients with carotid stenosis. Lancet (1987) 1.04
Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett (1998) 1.03
Stromelysin-3: a paradigm for stroma-derived factors implicated in carcinoma progression. Crit Rev Oncol Hematol (1997) 1.03
Quality assurance in radiotherapy: the importance of medical physics staffing levels. Recommendations from an ESTRO/EFOMP joint task group. Radiother Oncol (1996) 1.03
Bacteriophage lambda-E. coli K12 vector-host system for gene cloning and expression under lactose promoter control: I. DNA fragment insertion at the lacZ EcoRI restriction site. Mol Gen Genet (1979) 1.02
DL-a-Monofluoromethylputrescine is a potent irreversible inhibitor of Escherichia coli ornithine decarboxylase. Biochem J (1982) 1.02
Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem (2000) 1.02
Variation in the interaction between familial and reproductive factors on the risk of breast cancer according to age, menopausal status, and degree of familiality. Int J Epidemiol (2000) 1.01
Induction of endothelial cell apoptosis by solid tumor cells. Exp Cell Res (1998) 1.01
[Methodology of the development of diagnostic and therapeutic standards, options and recommendations in oncology]. Bull Cancer (1995) 1.01
Inhibition of human neutrophil elastase with peptidyl electrophilic ketones. 2. Orally active PG-Val-Pro-Val pentafluoroethyl ketones. J Med Chem (1994) 1.01
Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer (2010) 1.00
Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells. Exp Cell Res (2000) 1.00
Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol (1995) 1.00
Detection of errors in individual patients in radiotherapy by systematic in vivo dosimetry. Radiother Oncol (1995) 1.00
Matrix metalloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics. Allergy (2001) 0.99
Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer (1994) 0.99
MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease. J Neural Transm Park Dis Dement Sect (1989) 0.99
Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun (2001) 0.99
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol (2005) 0.98
[Enzymatic activities of the mitochondrial respiratory chain in child cardiomyopathies. 34 cases prospectively studied by endomyocardial biopsy]. Arch Mal Coeur Vaiss (1992) 0.98
PulO, a component of the pullulanase secretion pathway of Klebsiella oxytoca, correctly and efficiently processes gonococcal type IV prepilin in Escherichia coli. Mol Microbiol (1992) 0.98
MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis. Oncogene (2011) 0.98
[Oxygen therapy in hyaline membrane disease. Respiration in constant depression]. J Gynecol Obstet Biol Reprod (Paris) (1972) 0.97
Effect of alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues. Life Sci (1979) 0.97
Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol (1995) 0.96
Esophageal cancer: determination of internal target volume for conformal radiotherapy. Radiother Oncol (2006) 0.96
Catalytic irreversible inhibition of bacterial and plant arginine decarboxylase activities by novel substrate and product analogues. Biochem J (1987) 0.96
Bilateral periventricular nodular heterotopia in France: frequency of mutations in FLNA, phenotypic heterogeneity and spectrum of mutations. J Neurol Neurosurg Psychiatry (2009) 0.96
[Neonatal thrombosis of the aortic arch]. Pediatrie (1993) 0.96